Ginkgo Bioworks
Financials
Estimates*
USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Revenues | 76.7m | 314m | 478m | 251m | 185m | 211m | 255m |
% growth | 41 % | 309 % | 52 % | (47 %) | (27 %) | 14 % | 21 % |
EBITDA | (108m) | (1.9b) | (2.2b) | (633m) | (407m) | (200m) | (180m) |
% EBITDA margin | (140 %) | (598 %) | (456 %) | (252 %) | (220 %) | (95 %) | (71 %) |
Profit | (127m) | (1.8b) | (2.1b) | (893m) | (656m) | (390m) | (265m) |
% profit margin | (165 %) | (583 %) | (441 %) | (355 %) | (355 %) | (185 %) | (104 %) |
EV / revenue | - | 34.5x | 3.2x | 9.5x | -0.8x | -0.5x | -0.5x |
EV / EBITDA | - | -5.8x | -0.7x | -3.8x | 0.3x | 0.5x | 0.7x |
R&D budget | 160m | 1.1b | 1.1b | 581m | - | - | - |
R&D % of revenue | 208 % | 366 % | 220 % | 231 % | - | - | - |
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
N/A | Grant | ||
* | $180k | Grant | |
* | $1.3m | Grant | |
$400k | Grant | ||
$100k | Seed | ||
N/A | N/A | Convertible | |
$9.0m | Series A | ||
$45.0m | Series B | ||
$1.5m | Grant | ||
$100m | Series C | ||
* | $275m | Series D | |
$290m Valuation: $3.9b | Series E | ||
* | $70.0m Valuation: $3.9b 72.2x EV/LTM Revenues -48.2x EV/LTM EBITDA | Late VC | |
$1.7b Valuation: $17.5b 228.3x EV/LTM Revenues -162.8x EV/LTM EBITDA | SPAC IPO | ||
$775m Valuation: $17.5b 228.3x EV/LTM Revenues | SPAC Private Placement | ||
$15.9m | Post IPO Equity | ||
* | N/A | Grant | |
* | N/A | Grant | |
Total Funding | $1.6b |
Recent News about Ginkgo Bioworks
EditGinkgo Bioworks, headquartered in Boston, is a pioneering biotechnology company that leverages advanced cell programming technology to create innovative products across various industries. The company's platform enables the design and growth of custom organisms that can produce a wide range of products, from food ingredients to fragrances, and even therapeutics. Essentially, Ginkgo programs cells to act as tiny factories, producing valuable compounds and materials.
Ginkgo Bioworks serves a diverse array of clients, including companies in the food and beverage industry, pharmaceuticals, agriculture, and biosecurity sectors. For instance, they collaborate with Cronos Group to unlock new potentials in cannabinoids and with Moderna to optimize vaccine production processes. They also work with organizations like IARPA to enhance biosecurity measures.
The market Ginkgo operates in is vast and includes biotechnology, synthetic biology, and bioengineering. These are rapidly growing fields with significant potential for innovation and disruption. Ginkgo's business model is primarily based on partnerships and collaborations. They work closely with other companies to develop custom biological solutions tailored to specific needs. This collaborative approach not only drives innovation but also ensures a steady revenue stream through service fees, milestone payments, and royalties.
Ginkgo Bioworks makes money by providing its cell programming services to partner companies. They charge for the development and optimization of custom organisms and may also receive ongoing payments based on the success and commercial use of these organisms. Additionally, they may earn royalties from products developed using their technology.
In summary, Ginkgo Bioworks is at the forefront of biotechnology, using cell programming to create custom solutions for a wide range of industries. Their innovative approach and collaborative business model position them as a key player in the biotech market.
Keywords: biotechnology, cell programming, custom organisms, food ingredients, fragrances, therapeutics, biosecurity, synthetic biology, partnerships, innovation.